言語を選択

RAGE

RAGE 詳細

英語名	Advanced glycosylation end product-specific receptor	市販薬剤の数	0
治験薬の数	3	ターゲットの別称	Receptor for advanced glycosylation end products，AGER，Advanced Glycosylation End-Product Specific Receptor，RAGE，Receptor For Advanced Glycation End-Products Variant 20，Receptor For Advanced Glycation End-Products，RAGE Isoform NtRAGE-Delta，RAGE Isoform SRAGE-Delta，SCARJ1，Receptor for Advanced Glycation End Products，Advanced glycosylation end product-specific receptor
研究＆開発段階	Phase 3 Clinical

英語名	Advanced glycosylation end product-specific receptor
ターゲットの別称	Receptor for advanced glycosylation end products，AGER，Advanced Glycosylation End-Product Specific Receptor，RAGE，Receptor For Advanced Glycation End-Products Variant 20，Receptor For Advanced Glycation End-Products，RAGE Isoform NtRAGE-Delta，RAGE Isoform SRAGE-Delta，SCARJ1，Receptor for Advanced Glycation End Products，Advanced glycosylation end product-specific receptor
市販薬剤の数	0
治験薬の数	3
研究＆開発段階	Phase 3 Clinical

RAGE 製品リスト

属性
Cell (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
- (1)
マーカー
- (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
CHEK-ATP156	Human	HEK293	HEK293/Human RAGE Stable Cell Line

総数量1

RAGEバックグランド

Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

RAGE分子の別称

AGER,RAGE

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Azeliragon	TTP-488; PF-4494700; PF-04494700	Phase 3 Clinical	Vtv Therapeutics	Alzheimer Disease; Brain metastases; Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Diabetic Nephropathies; Glioblastoma; Glioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms	詳細
TRC-4186	TX-41XX; TRC-4186	Phase 2 Clinical	Torrent Pharmaceuticals Ltd	Diabetes Complications; Heart Failure	詳細
ARO-RAGE		Phase 2 Clinical	Arrowhead Pharmaceuticals Inc	Asthma	詳細